Prime Medicine, Inc. (NYSE:PRME – Free Report) – Stock analysts at Wedbush boosted their Q4 2024 earnings per share (EPS) estimates for shares of Prime Medicine in a research report issued on Monday, September 30th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings of ($0.28) per share for the quarter, up from their previous forecast of ($0.39). Wedbush currently has a “Outperform” rating and a $12.00 price target on the stock. The consensus estimate for Prime Medicine’s current full-year earnings is ($1.76) per share. Wedbush also issued estimates for Prime Medicine’s Q1 2025 earnings at ($0.28) EPS, Q2 2025 earnings at ($0.28) EPS, Q3 2025 earnings at ($0.27) EPS, Q4 2025 earnings at ($0.27) EPS, FY2025 earnings at ($1.11) EPS, FY2026 earnings at $0.21 EPS, FY2027 earnings at ($1.17) EPS and FY2028 earnings at ($1.23) EPS.
Prime Medicine (NYSE:PRME – Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.06).
Get Our Latest Analysis on Prime Medicine
Prime Medicine Trading Down 10.9 %
NYSE:PRME opened at $3.45 on Wednesday. Prime Medicine has a 12 month low of $3.39 and a 12 month high of $9.86. The stock has a 50 day moving average of $4.27 and a two-hundred day moving average of $5.46. The firm has a market cap of $414.11 million, a P/E ratio of -1.59 and a beta of 2.18.
Institutional Inflows and Outflows
Large investors have recently added to or reduced their stakes in the company. ORG Partners LLC purchased a new stake in shares of Prime Medicine during the second quarter worth $29,000. National Bank of Canada FI purchased a new stake in shares of Prime Medicine during the second quarter worth $34,000. Nisa Investment Advisors LLC increased its position in shares of Prime Medicine by 22,652.9% during the second quarter. Nisa Investment Advisors LLC now owns 7,736 shares of the company’s stock worth $40,000 after acquiring an additional 7,702 shares during the period. Chelsea Counsel Co. increased its position in shares of Prime Medicine by 733.3% during the fourth quarter. Chelsea Counsel Co. now owns 5,000 shares of the company’s stock worth $44,000 after acquiring an additional 4,400 shares during the period. Finally, IQ EQ FUND MANAGEMENT IRELAND Ltd purchased a new stake in shares of Prime Medicine during the second quarter worth $97,000. 70.37% of the stock is currently owned by institutional investors and hedge funds.
Prime Medicine Company Profile
Prime Medicine, Inc, a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence.
Featured Articles
- Five stocks we like better than Prime Medicine
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Why Lennar Stock Could Be the Best Play in the Housing Market
- Industrial Products Stocks Investing
- 2 Energy Stocks Fueling the AI Datacenter Boom
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Receive News & Ratings for Prime Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prime Medicine and related companies with MarketBeat.com's FREE daily email newsletter.